bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.09.10.750782

A frozen human wound-repair reference reveals heterogeneous tumor niches and conditional immunotherapy associations

Abstract

Purpose Tumors are often framed as unresolved wounds, but the extent to which independently defined physiological repair programs are recontextualized across cancers remains uncertain. Methods We derived five lineage-associated modules and a composite score from 58,823 cells in a longitudinal human skin-wound cohort before examining tumors. Frozen modules were evaluated in paired hepatocellular carcinoma and lung adenocarcinoma single-cell datasets, spatial and cell-resolved non-small-cell lung cancer cohorts, and four pretreatment immune-checkpoint-inhibitor cohorts. Patient- or section-level inference and prespecified sensitivity analyses were retained. Results Myeloid repair modules showed the most consistent tumor-associated increase in paired cancers; other lineage effects varied by context. Repair-high non-small-cell lung cancer regions combined epithelial/proliferative, extracellular-matrix fibroblast, and C1QC/broad-myeloid programs, whereas repair-cytotoxic neighborhood correlations were split across sections. In six Prime 5K Xenium patients, repair-high regions were fibroblast enriched (+0.239 high-minus-low fraction; 6/6 concordant; exact sign-flip P=0.031; FDR=0.047) and T/NK depleted (-0.151; 6/6; FDR=0.047). Direct ligand-receptor neighbor effects were not reproducible. Repair_FBI showed an adverse ICI-response direction, but the random-effects estimate was imprecise (OR=1.69, 95% CI 0.81-3.51). Conclusion Tumors reuse elements of physiological repair to form heterogeneous multicellular niches. Fibroblast remodeling is the most stable candidate; the evidence supports conditional association, not universal immune exclusion, a senescence-defined state, or a generlizable ICI biomarker.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

wu, q., liu, l., jiang, m. s.. 2026-09-16. A frozen human wound-repair reference reveals heterogeneous tumor niches and conditional immunotherapy associations. https://doi.org/10.64898/2026.09.10.750782

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Common viral infections seed regionally distinct resident memory T cells in the human CNS

T cells persist in the central nervous system (CNS) and can drive both protection and neurological disease. How these cells are organized in humans and what they recognize is largely unknown. Here, we profiled CD8 T cells across anatomically distinct CNS regions, obtained through on-site autopsies and temporal lobe resection surgeries, using single-cell RNA sequencing, paired T cell receptor sequencing, and DNA-barcoded tetramers. Resident memory T cells (TRM) specific for Epstein-Barr virus, cytomegalovirus, influenza A, and SARS-CoV-2 were identified across CNS compartments. Anatomical location was the strongest correlate of TRM cell state, with leptomeningeal cells adopting a cytokine-poised TRM program, whereas brain TRM cells were transcriptionally restrained. Cells of the same clonotype spanned tissues yet adopted local transcriptional states. Viral specificity added another layer of TRM heterogeneity with GZMK/GZMA-expressing EBV-specific populations and interferon-stimulated gene signatures in SARS-CoV-2 and Influenza A-specific cells. The human CNS thus harbors regionally distinct CD8+ TRM shaped by common viral exposures.

immunology↗

A regulatory T cell signature provides a shared molecular basis for the therapeutic window of opportunity in rheumatic disease

Rheumatic diseases, including rheumatoid arthritis (RA), spondyloarthritis (SpA) and osteoarthritis (OA), show distinct phenotypes yet respond to overlapping therapies, implicating shared immune mechanisms. In the Transimmunom cohort, we profiled peripheral blood from 240 individuals (47 healthy, 44 OA, 91 RA, 58 SpA) across deep immunophenotyping, immunoproteomics and Treg-Teff transcriptomics. Single-layer analyses revealed broader Treg than Teff remodeling, along with a shared pattern of reduced activated Tregs and expanded Helios+ Tregs across all diseases, alongside a decrease in functional Treg subpopulations, including CTLA4+ and CD45RA- Tregs. In RA specifically, LAG3+ Tregs were also expanded. Combining omics layers outperformed single-layer approaches for disease classification. Among individual layers, Treg transcriptomes were most discriminative, and integration uncovered disease-specific programs. Unsupervised clustering identified a cross-disease cluster independent of activity, treatment and age, mapping to early disease (<= years) and dominated by a Treg dysfunction-associated program. These results provide a biological rationale for the therapeutic "window of opportunity" concept and duration-stratified Treg-directed trials.

immunology↗

Inhibitory Fc Receptor sets a time limit on macrophage response to IgG

Antibodies engage both activating Fc Receptors and the inhibitory receptor Fc{gamma}RIIB. Why macrophages need a dedicated inhibitory receptor rather than simply tuning activating receptor signaling is unclear. Using DNA-based chimeric receptors and in silico modeling, we independently controlled activating and inhibitory Fc Receptors. We found that Fc{gamma}RIIB imposed a time limit on macrophage phagocytosis and ERK signaling. The time limit is due to activating Fc Receptors converting PI(4,5)P2 to PI(3,4,5)P3, which is subsequently converted to PI(3,4)P2 by Fc{gamma}RIIB. This leads to a pulse of active signaling, which is sufficient for phagocytosis of small bacteria-sized targets but not phagocytosis of large targets and TNF secretion. Unlike engaging Fc{gamma}RIIB, reducing activating Fc Receptor signaling decreased initiation of phagocytosis, the speed of PI(3,4,5)P3 generation, and the amplitude of ERK signaling. Our results demonstrate that Fc{gamma}RIIB controls the duration of IgG signaling, while the activating Fc Receptors control sensitivity.

immunology↗